Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma
Liver International · 2026
DOI: 10.1111/liv.70806 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, 2026. Verfasst von Zobair M Younossi und 59 weiteren Autor:innen. Beteiligte Einrichtung: Global NASH/MASH Council, Washington, DC, USA. Hauptthemen laut MEDLINE: Hypertension, Portal, Liver Neoplasms, Carcinoma, Hepatocellular, Hepatitis, Viral, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Global NASH/MASH Council, APADRMF association pour la recherche sur les maladies du foie.
Abstract (Originalsprache)
The Paris International Liver Meeting (January 19–21, 2026) brought together leading hepatology experts to discuss transformative advances in chronic liver disease management. The meeting highlighted pivotal developments reflecting the field's evolution from disease characterisation toward precision, mechanism‐based therapeutics. Metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‐associated steatohepatitis (MASH), were highlighted, marking the transition to an era of approved disease‐modifying therapies. Resmetirom and semaglutide are now approved for MASH with F2–F3 fibrosis, with a robust pipeline generating anti‐fibrotic signals through FGF21 analogs, pan‐peroxisome proliferator‐activated receptor (PPAR) agonists, and incretin‐based dual and triple agonists. Non‐invasive tests have evolved beyond their original diagnostic role to enable prognostic stratification, screening of at‐risk populations, treatment selection, and monitoring of therapeutic response. This evolution is not limited to MASLD, but extends to other chronic liver diseases, including primary biliary cholangitis (PBC) and portal hypertension, as highlighted by the recommendations of the Baveno Consensus Workshops. Hepatitis B and D are moving toward functional cure strategies, with simplified HBV treatment algorithms based on fibrosis and viral load, supported by biomarkers for risk stratification and safe treatment discontinuation. In parallel, HDV management is transitioning from a severe disease to one with emerging suppressive and potential curative l through bulevirtide and novel HBsAg‐targeting and RNA‐silencing therapies, respectively. Management of PBC has advanced with novel PPAR agonists that improve cholestatic biochemistry and pruritus, supported by individualised risk stratification. However, significant treatment gaps persist, with fewer than half of eligible PBC patients receiving second‐line therapy, and fatigue remains a major unmet clinical need. Furthermore, effective pharmacotherapies for primary sclerosing cholangitis (PSC) remain a major challenge, and no approved disease‐modifying treatments are currently available. Finally, for patients with hepatocellular carcinoma (HCC), immunotherapy combinations can achieve unprecedented long‐term survival in selected populations of patients. Collectively, these advances define a new era of hepatology centered on precision medicine, earlier intervention, and mechanism‐driven therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global NASH/MASH Council, Washington, DC, USA.
- Global Center for Liver Outcomes & Policy Research, Georgetown University School of Medicine, Washington, DC, USA.
- 1st Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens 'Laiko', Athens, Greece.
- University College of London, UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK.
- Hepatology-Internal Medicine, Vall D'hebron University Hospital, Barcelona, Spain.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
ORCID-Profile: Zobair M Younossi, George Papatheodoridis, Emmanuel Tsochatzis, Maria Buti, Lorenza Rimassa, Ana Lleo, Debbie Shawcross, Frank Tacke, Vincent Wai-Sun Wong, Shira Zelber-Sagi, Andreas E Kremer, Paolo Angeli, Tarik Asselah, Nicola Pugliese, Cyrielle Caussy, Pietro Lampertico, Markus Cornberg, Mads Israelsen, Sabela Lens, Hannes Hagström, Paul Brennan, Mark Thursz, Claire Carette, Elisabetta Degasperi, Jean-François Dufour, Sven Francque, Claire Francoz, Jean-François Gautier, Helena Hernandez-Evole, Maurice Michel, Christophe Moreno, Thomas Mouillot, Lucia Parlati, Jean-Michel Pawlotsky, Pierre-Emmanuel Rautou, Thomas Reiberger, Michael Betel, Valérie Vilgrain, Elise Vuille-Lessard, Adrian Gadano, Jörn M Schattenberg, Maja Thiele
Förderung
- The Global NASH/MASH Council
- APADRMF association pour la recherche sur les maladies du foie
Zitieren
APA
Younossi, Z. M., Papatheodoridis, G., Tsochatzis, E., Buti, M., Rimassa, L., Pinzani, M., Lleo, A., Shawcross, D., Tacke, F., Wong, V. W., Zelber-Sagi, S., Kremer, A. E., J Pinato, D., M Llovet, J., Angeli, P., Asselah, T., Pugliese, N., Caussy, C., Berzigotti, A., …, & Thiele, M. (2026). Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma. Liver International. https://doi.org/10.1111/liv.70806
Vancouver
Younossi ZM, Papatheodoridis G, Tsochatzis E, Buti M, Rimassa L, Pinzani M, et al. Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma. Liver International. 2026. doi:10.1111/liv.70806
BibTeX
@article{Younossi2026,
author = {Younossi, Zobair M and Papatheodoridis, George and Tsochatzis, Emmanuel and Buti, Maria and Rimassa, Lorenza and Pinzani, Massimo and Lleo, Ana and Shawcross, Debbie and Tacke, Frank and Wong, Vincent Wai-Sun and Zelber-Sagi, Shira and Kremer, Andreas E and J Pinato, David and M Llovet, Josep and Angeli, Paolo and Asselah, Tarik and Pugliese, Nicola and Caussy, Cyrielle and Berzigotti, Annalisa and Lampertico, Pietro and Cornberg, Markus and Israelsen, Mads and Gines, Pere and Lens, Sabela and Hagström, Hannes and Trauner, Michael and Brennan, Paul and Boursier, Jérôme and Brunetto, Maurizia and Thursz, Mark and Bugianesi, Elisabetta and Carette, Claire and Degasperi, Elisabetta and Durand, François and Dufour, Jean-François and Francque, Sven and Francoz, Claire and Gautier, Jean-François and Hernandez-Evole, Helena and Jones, David and Michel, Maurice and Moreno, Christophe and Mouillot, Thomas and Parlati, Lucia and Pawlotsky, Jean-Michel and Rautou, Pierre-Emmanuel and Reiberger, Thomas and Roux, Olivier and Betel, Michael and Thabut, Dominique and Noureddin, Mazen and Vilgrain, Valérie and Vuille-Lessard, Elise and Yilmaz, Yusuf and Gadano, Adrian and Ratziu, Vlad and Schattenberg, Jörn M and Bataller, Ramon and Serfaty, Lawrence and Thiele, Maja},
title = {Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70806}
}
EUVIMED